GlassScriptPhysician profile
Karen Browning
NPI 1962765446
$2,659.23
in general payments reported to CMS, 2019-2025
28 companies · $647 in 2025
The $647 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $30.24 · 2021: $214 · 2022: $745 · 2023: $365 · 2024: $276 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $333.59 | 2022-2025 | Slynd |
| Abbvie INC. | $298.35 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $203.23 | 2019-2025 | |
| Pfizer INC. | $202.21 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $178.08 | 2021-2023 | |
| Myovant Sciences INC. | $175.70 | 2021-2022 | |
| Sage Therapeutics, LLC | $175.36 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $134.81 | 2019-2025 | Paragard T 380a, Endosee |
| Agile Therapeutics, INC. | $134.50 | 2021-2023 | Twirla |
| Sumitomo Pharma America, INC. | $105.78 | 2023-2025 | Myfembree, Gemtesa |
| Mylan Pharmaceuticals INC. | $103.99 | 2021-2022 | |
| Scynexis, INC. | $68.04 | 2022 | |
| Merck Sharp & Dohme LLC | $58.16 | 2019 | |
| Evofem Biosciences, INC. | $55.37 | 2021-2022 | |
| Therapeuticsmd, INC. | $54.58 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $49.78 | 2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $43.01 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $38.70 | 2022 | |
| Shield Therapeutics INC | $35.38 | 2024 | |
| Roche Diagnostics Corporation | $34.84 | 2019 | |
| Avion Pharmaceuticals | $34.61 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $32.00 | 2019 | |
| Allergan, INC. | $23.41 | 2019 | |
| Hologic Sales and Service, LLC | $20.68 | 2022 | |
| Becton, Dickinson and Company | $18.94 | 2020 | |
| Boston Scientific Corporation | $18.74 | 2019 | |
| Lupin INC. | $14.27 | 2019 | |
| Medicem INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.